Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Profit After Tax (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Profit After Tax for 14 consecutive years, with -$883820.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax rose 26.21% year-over-year to -$883820.0, compared with a TTM value of -$6.0 million through Sep 2025, down 41.81%, and an annual FY2024 reading of -$5.1 million, down 13.94% over the prior year.
  • Profit After Tax was -$883820.0 for Q3 2025 at Sunshine Biopharma, up from -$1.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $667116.0 in Q4 2021 and bottomed at -$23.5 million in Q4 2022.
  • Average Profit After Tax over 5 years is -$2.8 million, with a median of -$1.3 million recorded in 2023.
  • Peak annual rise in Profit After Tax hit 161.55% in 2021, while the deepest fall reached 6461.84% in 2021.
  • Year by year, Profit After Tax stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then skyrocketed by 59.05% to -$883820.0 in 2025.
  • Business Quant data shows Profit After Tax for SBFM at -$883820.0 in Q3 2025, -$1.8 million in Q2 2025, and -$1.2 million in Q1 2025.